SGCA
KERX

Steel Grove Capital Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Steel Grove Capital Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-23,650
Closed -$80K – 350
2018
Q3 		$80K Hold
23,650
– – 0.01% 307
2018
Q2 		$89K Hold
23,650
– – 0.01% 303
2018
Q1 		$97K Hold
23,650
– – 0.02% 299
2017
Q4 		$110K Hold
23,650
– – 0.02% 292
2017
Q3 		$168K Hold
23,650
– – 0.03% 273
2017
Q2 		$171K Hold
23,650
– – 0.03% 262
2017
Q1 		$146K Sell
23,650
-1,850
-7% -$10.1K 0.03% 265
2016
Q4 		$149K Hold
25,500
– – 0.03% 242
2016
Q3 		$135K Buy
+25,500
New +$137K 0.03% 192

Steel Grove Capital Advisors's KERX Position: Q4 2018 in Review

Steel Grove Capital Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 23,650 shares — an estimated $80K sold.

Steel Grove Capital Advisors first reported a position in KERX in Q3 2016 and held it in 9 quarters. The position peaked at $171K in Q2 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

  • Steel Grove Capital Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Steel Grove Capital Advisors sold 23,650 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $80K.
  • Steel Grove Capital Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q3 2016 and held it in 9 quarters.
  • Steel Grove Capital Advisors's Keryx Biopharmaceuticals Inc position peaked at $171K in Q2 2017.
  • 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on Steel Grove Capital Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.